Phase II Study of Neoadjuvant Chemotherapy With Doxorubicin Followed by Docetaxel-Cisplatin in Locally Advanced Breast Cancer
Sponsor
King Faisal Specialist Hospital & Research Center (Other)
Overall Status
Completed
CT.gov ID
NCT00538525
Collaborator
(none)
10
1
7
Study Details
Study Description
Brief Summary
Phase II study of neoadjuvant chemotherapy with Doxorubicin followed by Docetaxel-Cisplatin in locally advanced breast cancer
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Study Type:
Interventional
Actual Enrollment
:
10 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Study Start Date
:
Sep 1, 2007
Actual Primary Completion Date
:
Apr 1, 2008
Actual Study Completion Date
:
Apr 1, 2008
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Arm 1 Doxorubicin, Docetaxel, Cisplatin |
Drug: Doxorubicin, Docetaxel, Cisplatin
Doxorubicin, Docetaxel, Cisplatin
|
Outcome Measures
Primary Outcome Measures
- Effectiveness [overall]
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Patients with locally advanced breast cancer
Exclusion Criteria:
- Patients with metastatic breast cancer
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- King Faisal Specialist Hospital & Research Center
Investigators
- Principal Investigator: Adnan Ezzat, MD, KFSH&RC, Riyadh, Saudi Arabia
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier:
NCT00538525
Other Study ID Numbers:
- RAC#2011-022
First Posted:
Oct 2, 2007
Last Update Posted:
May 30, 2012
Last Verified:
May 1, 2012